Previous Close | 21.49 |
Open | 21.50 |
Bid | 15.51 x 200 |
Ask | 27.60 x 200 |
Day's Range | 21.43 - 21.51 |
52 Week Range | 2.31 - 21.58 |
Volume | |
Avg. Volume | 2,077,195 |
Market Cap | 1.82B |
Beta (5Y Monthly) | -0.72 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Fusion Pharmaceuticals (FUSN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Fusion (FUSN) is expected to provide updates regarding the developmental program of its lead candidate, FPI-2265, for prostate cancer in the first-quarter earnings release.
Fusion Pharmaceuticals Inc. (FUSN) concluded the recent trading session at $21.42, signifying a +0.63% move from its prior day's close.